DARMSTADT, GERMANY: Merck said that BioInvent International AB, a Swedish company will upgrade and expand its drug discovery with a comprehensive range of Mobius disposable bioreactors manufactured by Merck.
BioInvent is developing novel immuno regulatory antibodies for cancer therapy.
BioInvent will use bioreactors at 3, 50, 200 and 1000 litres in its upstream facility in Lund, Sweden, thereby enhancing flexibility and scalability alongside extended capacity. Merck's Mobius disposable bioreactor portfolio from 3 to 2000 litres provides industry-leading advantages with more flexibility and continuity for scale-up: the training needs of specialists can be reduced within the framework of scale-up.
“Our comprehensive portfolio of single-use technologies is geared to young biopharmaceutical companies and established drug developers such as BioInvent, who are looking to increase productivity,” said Udit Batra, a member of Merck's executive board and CEO of the life science division.
“We offer the full range of bioreactors, services, and support that will help BioInvent deliver innovative therapeutics faster through the development pipeline. The company is upgrading the BioInvent facility (including a 1000-liter disposable bioreactor) to meet production requirements for their own development projects in the field of novel antibodies as well as for BioInvent customers worldwide, added Batra.
“BioInvent has been researching and producing antibodies for more than 30 years. Therefore, we have set the highest standards when it comes to upgrading our disposable production line,” said Kristoffer Rudenholm Hansson, VP of technical operations, BioInvent.
© Chemical Today News
Read More: Merck provides disposable bioreactors manufacturing capabilities to BioInvent
No comments:
Post a Comment